Adrenomedullin Improves Hypertension and Vascular Remodeling partly through the Receptor-Mediated AMPK Pathway in Rats with Obesity-Related Hypertension.

Adrenomedullin (ADM) is a novel cardiovascular peptide with anti-inflammatory and antioxidant properties. Chronic inflammation, oxidative stress and calcification play pivotal roles in the pathogenesis of vascular dysfunction in obesity-related hypertension (OH). Our study aimed to explore the effects of ADM on the vascular inflammation, oxidative stress and calcification in rats with OH. Eight-week-old Sprague Dawley male rats were fed with either a Control diet or a high fat diet (HFD) for 28 weeks. Next, the OH rats were randomly subdivided into two groups as follows: (1) HFD control group, and (2) HFD with ADM. A 4-week treatment with ADM (7.2 µg/kg/day, ip) not only improved hypertension and vascular remodeling, but also inhibited vascular inflammation, oxidative stress and calcification in aorta of rats with OH. In vitro experiments, ADM (10 nM) in A7r5 cells (rat thoracic aorta smooth muscle cells) attenuated palmitic acid (PA, 200 µM) or angiotensin II (Ang II, 10 nM) alone or their combination treatment-induced inflammation, oxidative stress and calcification, which were effectively inhibited by the ADM receptor antagonist ADM22-52 and AMP-activated protein kinase (AMPK) inhibitor Compound C, respectively. Moreover, ADM treatment significantly inhibited Ang II type 1 receptor (AT1R) protein expression in aorta of rats with OH or in PA-treated A7r5 cells. ADM improved hypertension, vascular remodeling and arterial stiffness, and attenuated inflammation, oxidative stress and calcification in OH state partially via receptor-mediated AMPK pathway. The results also raise the possibility that ADM will be considered for improving hypertension and vascular damage in patients with OH.

[Effection of compositie salviae dropping pill on hyperlipemia patients with phlegm and blood stasis syndrome].

OBJECTIVE: To explore the effect of compositie salviae dropping pill (CSDP) on hyperlipemia patients with phlegm and blood stasis syndrome. METHOD: Hyperlipemia patients were divided randomly into two groups. One group of 40 patients were treated by CSDP, another group of 41 patients were treated by simvastatin. The TC, TG, HDL-C, LDL-C, ApoA and ApoB levels, ALT, r-GT, IL-6, MDA level and SOD activity were determined before and after being treated. RESULT: After 3 months treatment, the TC, TG and LDL-C levels were obviously decreased in two groups (P <0.01, P < 0.05), there is no significant difference between the effective rate of two groups. The ALT, r-GT, IL-8 and MDA levels of treatment group were obviously decreased (P < 0.01, P < 0.05), while the ApoA level and SOD activity increased obviously in those patients (P <0.05, P <0.01, respectively). However, the ALT, r-GT, IL-6, MDA, HDL-C, ApoA level and SOD activity had no significant difference after treatment in control group. CONCLUSION: Our study suggest that CSDP have the function of falling serum lipid level without damaging liver function, its function of protecting liver function might related to its function of improving of anti-oxidation and decreasing of inflammation, the mechanism of CSDP disparting and removing phlem and blood stasis in the processes lipid metabolism need to be studied further.